790 related articles for article (PubMed ID: 18474519)
1. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity.
Krumbholz M; Faber H; Steinmeyer F; Hoffmann LA; Kümpfel T; Pellkofer H; Derfuss T; Ionescu C; Starck M; Hafner C; Hohlfeld R; Meinl E
Brain; 2008 Jun; 131(Pt 6):1455-63. PubMed ID: 18474519
[TBL] [Abstract][Full Text] [Related]
2. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
[TBL] [Abstract][Full Text] [Related]
3. TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties.
Mackay F; Schneider P
Cytokine Growth Factor Rev; 2008; 19(3-4):263-76. PubMed ID: 18514565
[TBL] [Abstract][Full Text] [Related]
4. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome.
Ittah M; Miceli-Richard C; Eric Gottenberg J; Lavie F; Lazure T; Ba N; Sellam J; Lepajolec C; Mariette X
Arthritis Res Ther; 2006; 8(2):R51. PubMed ID: 16507175
[TBL] [Abstract][Full Text] [Related]
5. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production.
Hedegaard CJ; Sellebjerg F; Krakauer M; Hesse D; Bendtzen K; Nielsen CH
Mult Scler; 2011 May; 17(5):567-77. PubMed ID: 21177756
[TBL] [Abstract][Full Text] [Related]
6. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling.
Mackay F; Silveira PA; Brink R
Curr Opin Immunol; 2007 Jun; 19(3):327-36. PubMed ID: 17433868
[TBL] [Abstract][Full Text] [Related]
7. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.
Day ES; Cachero TG; Qian F; Sun Y; Wen D; Pelletier M; Hsu YM; Whitty A
Biochemistry; 2005 Feb; 44(6):1919-31. PubMed ID: 15697217
[TBL] [Abstract][Full Text] [Related]
8. Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus.
Chu VT; Enghard P; Schürer S; Steinhauser G; Rudolph B; Riemekasten G; Berek C
Arthritis Rheum; 2009 Jul; 60(7):2083-93. PubMed ID: 19565488
[TBL] [Abstract][Full Text] [Related]
9. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy.
Kim SJ; Lee SJ; Choi IY; Park Y; Choi CW; Kim IS; Yu W; Hwang HS; Kim BS
Eur J Haematol; 2008 Sep; 81(3):177-84. PubMed ID: 18510703
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes.
Matsushita T; Hasegawa M; Yanaba K; Kodera M; Takehara K; Sato S
Arthritis Rheum; 2006 Jan; 54(1):192-201. PubMed ID: 16385515
[TBL] [Abstract][Full Text] [Related]
11. The expression of BAFF-binding receptors is not altered in multiple sclerosis or myasthenia gravis.
Thangarajh M; Kisiswa L; Pirskanen R; Hillert J
Scand J Immunol; 2007 May; 65(5):461-6. PubMed ID: 17444957
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF.
Matsushita T; Fujimoto M; Hasegawa M; Tanaka C; Kumada S; Ogawa F; Takehara K; Sato S
J Rheumatol; 2007 Oct; 34(10):2056-62. PubMed ID: 17896803
[TBL] [Abstract][Full Text] [Related]
13. BAFF, APRIL, TWE-PRIL: who's who?
Daridon C; Youinou P; Pers JO
Autoimmun Rev; 2008 Feb; 7(4):267-71. PubMed ID: 18295728
[TBL] [Abstract][Full Text] [Related]
14. APRIL and BAFF proteins increase proliferation of human adipose-derived stem cells through activation of Erk1/2 MAP kinase.
Zonca M; Mancheño-Corvo P; DelaRosa O; Mañes S; Büscher D; Lombardo E; Planelles L
Tissue Eng Part A; 2012 Apr; 18(7-8):852-9. PubMed ID: 22059379
[TBL] [Abstract][Full Text] [Related]
15. Analysis of BAFF and TRAIL expression levels in multiple sclerosis patients: evaluation of expression under immunomodulatory therapy.
Kurne A; Guc D; Canpinar H; Aydin OF; Sayat G; Yörübulut M; Esendagli G; Karabudak R
Acta Neurol Scand; 2011 Jan; 123(1):8-12. PubMed ID: 20456241
[TBL] [Abstract][Full Text] [Related]
16. Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis.
Thangarajh M; Gomes A; Masterman T; Hillert J; Hjelmström P
J Neuroimmunol; 2004 Jul; 152(1-2):183-90. PubMed ID: 15223251
[TBL] [Abstract][Full Text] [Related]
17. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.
Salazar-Camarena DC; Ortíz-Lazareno P; Marín-Rosales M; Cruz A; Muñoz-Valle F; Tapia-Llanos R; Orozco-Barocio G; Machado-Contreras R; Palafox-Sánchez CA
Cytokine; 2019 Feb; 114():115-127. PubMed ID: 30467093
[TBL] [Abstract][Full Text] [Related]
18. Serum BAFF and APRIL levels in patients with PBC.
Migita K; Ilyassova B; Kovzel EF; Nersesov A; Abiru S; Maeda Y; Komori A; Ito M; Yano K; Yatsuhashi H; Shimoda S; Ishibashi H; Nakamura M
Clin Immunol; 2010 Feb; 134(2):217-25. PubMed ID: 19840904
[TBL] [Abstract][Full Text] [Related]
19. Increased BCMA expression in lupus marks activated B cells, and BCMA receptor engagement enhances the response to TLR9 stimulation.
Kim J; Gross JA; Dillon SR; Min JK; Elkon KB
Autoimmunity; 2011 Mar; 44(2):69-81. PubMed ID: 21250838
[TBL] [Abstract][Full Text] [Related]
20. Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion.
Katsenelson N; Kanswal S; Puig M; Mostowski H; Verthelyi D; Akkoyunlu M
Eur J Immunol; 2007 Jul; 37(7):1785-95. PubMed ID: 17557373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
